Internal Medicine, Hematology & Oncology · Knoxville, TN
NPI
1023018728
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
9957 Sherrill Blvd
Knoxville, TN, 37932
Phone (865) 639-2255
Groups this clinician bills Medicare through
Medicare paid, 2024
$9.7M
464,884 services
Medicare patients, 2024
968
Average age 76
Drug cost, 2024
$4.6M
1,364 prescriptions
Company payments, 2025
$3,684
From 34 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ross E Kerns was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 38,600 times for 32 patients. In total Ross E Kerns billed 464,884 services in 180 codes, and Medicare paid $9.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 38,600 | 32 | $2.33 | $90K |
| J0897 Injection, denosumab, 1 mg | Office | 33,180 | 179 | $20.49 | $680K |
| J9299 Injection, nivolumab, 1 mg | Office | 29,700 | 12 | $24.56 | $730K |
| J0185 Injection, aprepitant, 1 mg | Office | 22,490 | 34 | $1.34 | $30K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 21,780 | 15 | $39.04 | $850K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 20,200 | 17 | $44.60 | $901K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 19,008 | 32 | $21.18 | $403K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 14,790 | 15 | $0.27 | $4,019 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 14,400 | 101 | $15.77 | $227K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 9,840 | 17 | $32.98 | $325K |
| J9171 Injection, docetaxel, 1 mg | Office | 4,765 | 14 | $0.70 | $3,358 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 4,687 | 69 | $0.09 | $412 |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 4,290 | 13 | $31.84 | $137K |
| Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Office | 3,529 | 11 | $51.94 | $183K |
| 85025 Blood Count | Office | 3,320 | 802 | $7.57 | $25K |
By year: 2022 $10.2M for 563,472 services; 2023 $9.6M for 476,749 services; 2024 $9.7M for 464,884 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 3,320 | 802 | $7.57 | $25K |
| 80053 Clinical Chemistry | 3,026 | 806 | $10.32 | $31K |
| 36415 Venipuncture Blood Collection | 2,740 | 783 | $8.58 | $24K |
| 88185 Surgical Pathology Examination | 2,022 | 76 | $16.20 | $33K |
| 83615 Clinical Chemistry | 1,207 | 551 | $5.91 | $7,137 |
| 82784 Immunoassay | 1,033 | 189 | $9.06 | $9,356 |
| 82728 Clinical Chemistry | 802 | 389 | $13.29 | $11K |
| 83550 Clinical Chemistry | 793 | 387 | $8.51 | $6,751 |
| 83540 Clinical Chemistry | 792 | 386 | $6.30 | $4,992 |
| 83521 Immunoassay | 560 | 143 | $16.79 | $9,400 |
Medicare prescription drug claims, 2024
In 2024, the drug Ross E Kerns prescribed most often to Medicare patients was Anastrozole, with 151 prescriptions and refills. In total Ross E Kerns wrote 1,364 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 151 | 420 | 53 | $2,317 |
| Hydroxyurea Generic | 56 | 131 | 20 | $1,551 |
| Potassium Chloride Generic | 54 | 71 | 24 | $631 |
| Allopurinol Generic | 52 | 99 | 17 | $356 |
| Prednisone Generic | 51 | 81 | 18 | $320 |
| Revlimid Lenalidomide | 49 | 49 | Under 11 | $727K |
| Omeprazole Generic | 44 | 112 | 14 | $329 |
| Pomalyst Pomalidomide | 44 | 44 | Under 11 | $787K |
| Valacyclovir Valacyclovir Hcl | 40 | 82 | 11 | $1,591 |
| Ondansetron Hcl Generic | 38 | 38 | 18 | $145 |
| Eliquis Apixaban | 37 | 47 | 11 | $26K |
| Lenalidomide Generic | 35 | 35 | Under 11 | $420K |
| Keytruda Pembrolizumab | 33 | 35 | Under 11 | $422K |
| Letrozole Generic | 30 | 74 | 13 | $522 |
| Jakafi Ruxolitinib Phosphate | 30 | 30 | Under 11 | $323K |
Brand drugs: 417 claims; generic drugs: 947 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ross E Kerns $3,684 ($3,684 in general payments such as food, travel and fees) from 34 companies. The largest payer was Novartis Pharmaceuticals Corporation with $397.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 20 | $397 |
| E.R. Squibb & Sons, L.L.C. BMY | 18 | $386 |
| Janssen Biotech, Inc. JNJ | 12 | $250 |
| Incyte Corporation INCY | 10 | $236 |
| Pfizer Inc. PFE | 11 | $220 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $204 |
| Merck Sharp & Dohme LLC MRK | 7 | $179 |
| Regeneron Healthcare Solutions, Inc. REGN | 8 | $176 |
| Deciphera Pharmaceuticals Inc. | 6 | $141 |
| Gilead Sciences, Inc. GILD | 6 | $138 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.